Impact of nivolumab vs standard, single-agent therapy of investigator’s choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141, a randomized, phase 3 trial

BACKGROUND: Patients with platinum-refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Harrington, Kevin J, Ferris, Robert L, Blumenschein, George, Colevas, A Dimitrios, Fayette, Jerome, Licitra, Lisa, Kasper, Stefan, Even, Caroline, Vokes, Everett E, Worden, Francis, Saba, Nabil F, Kiyota, Naomi, Haddad, Robert, Tahara, Makoto, Grünwald, Viktor, Shaw, James W, Monga, Manish, Lynch, Mark, Taylor, Fiona, DeRosa, Michael, Morrissey, Laura, Cocks, Kim, Gillison, Maura L, Guigay, Joel
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461049/
https://ncbi.nlm.nih.gov/pubmed/28651929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30421-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi